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Abstract 
Words: 199 (Max 200 words) 
Objective: To examine the effect of providing a financial incentive to authors of randomized 
clinical trials (RCTs) to obtain individual patient data (IPD). 
Study Design and Setting: Parallel-group RCT with authors identified in the RCTs eligible for 
two systematic reviews. The authors were randomly allocated to the intervention (financial 
incentive with several contact approaches) or control group (using the same contact 
approaches). Studied outcomes: proportion of authors who provided IPD, time to obtain IPD, 
and completeness of IPD received. 
Results: Of the 129 authors contacted, 37 authors suggested or contacted a person/funder 
providing relevant details or showed interest to collaborate, while 45 authors directed us to 
contact a person/funder, lacked resources/time, did not have ownership/approval to share the 
IPD, or claimed IPD was too old. None of the authors shared their IPD. We contacted 17 
sponsors and received two complete IPD datasets from one sponsor. The time to obtain IPD was 
>1 year after a sponsor’s positive response. Common barriers included study identification, data 
ownership, limited data access, and required IPD licenses. 
Conclusions: IPD sharing may depend on study characteristics, including funding type, study 
size, study risk of bias, and treatment effect, but not on providing a financial incentive.  
 
Trial registration: Clinical Trials.gov (NCT02569411), registered on October 5th, 2015. 
Keywords: meta-analysis, patient-level data, individual participant data, incentive, data 
retrieval, data sharing 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
4 
What is New? 
Key Findings 
• Significant barriers were encountered in obtaining study individual participant data 
(IPD). These included identifying trial data based on published reports and other 
sources, negotiating data ownership (for both authors and sponsors), and limited data 
access (including time, ability to share data, and special software needed) 
What this adds to what is known? 
• Likelihood of sharing IPD may be associated with study-specific characteristics, such as 
funding type, study size, study risk of bias, and treatment effect. For example, authors of 
publicly-sponsored studies with medium-large treatment effect (i.e., an estimated 
treatment effect above 0.2 on the standardized mean difference scale) tended to 
respond positively to IPD requests. Availability of IPD from sponsors tended to be 
positive for large studies with a low risk of bias 
• The time taken to obtain IPD was longer than a year after a sponsor’s positive response. 
Data sharing agreements were required for all sponsors. Clarifications from sponsors 
regarding the agreements ranged between 0 and 24 days. Approval of data sharing 
agreements ranged between 86 and 168 days 
What is the implication and what should change now? 
• Sharing IPD has legal, ethical, and logistical constraints, which may deter researchers 
from embarking on these projects and may deter trial participants from participating. 
This may reinforce reliance on aggregate data (network) meta-analysis that may have 
inadequate statistical power and accuracy, reducing the quality of evidence available to 
health professionals, policymakers, and patients.  
• Our findings show that obtaining study IPD can take longer than a year after a sponsor’s 
positive response. Therefore, we recommend that future planning of IPD meta-analyses 
should provide sufficient time (e.g. at least two years) for the IPD retrieval process, 
particularly in clinical areas where the approach is not yet established. 
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1. Introduction 1 
The synthesis of data from multiple randomized clinical trials (RCTs) may strengthen 2 
scientific evidence used by health professionals and policymakers; the gold standard analysis 3 
approach is pooling individual patient data (IPD) from RCTs of clinical interventions. [1-7] 4 
Several methods have been developed to use IPD in meta-analysis [6] and network meta-5 
analysis (NMA) [8] and their use has increased over the years, [8, 9] because meta-analyses or 6 
NMAs based on aggregated data have limitations.  In particular, IPD can be used to explain the 7 
variation of treatment effects between studies within pairwise comparisons (heterogeneity) 8 
and the variation of treatment effects between pairwise comparisons (inconsistency). [9-13] 9 
For example, a pooled estimate based on aggregate data with substantially heterogeneous 10 
treatment effect estimates may not be informative and an exploration of whether the treatment 11 
effects differ across pre-specified, clinically important subgroups may be needed. Although 12 
meta-regression aims to answer this, it has many limitations, such as 'aggregation bias'. [14] 13 
Aggregation bias arises when one incorrectly assumes that relationships observed at the group 14 
level hold also at the patient level and is also known as ecological bias. [15-17] The use of IPD 15 
can result in greater statistical power to detect patient-treatment relationships and help 16 
individualise management for patients with certain characteristics. Hence, confidence in meta-17 
analysis results can increase by including IPD on all randomized patients, irrespective of 18 
whether they were included in analyses of the primary RCT. 19 
Technological advances, such as safeguarding confidential data through secured 20 
platforms, have potential to increase the feasibility of obtaining IPD and there is a strong 21 
impetus to share anonymized IPD from RCTs. [18-31] However, it has been suggested that 22 
reluctance to share data is still the main obstacle for obtaining IPD and performing IPD meta-23 
analysis. [32, 33] Potential reasons for this include concerns about patient confidentiality, lack 24 
of time to share IPD, not ‘owning’ the data, cost for de-identifying and formatting the data, or 25 
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lack of access to data by primary study authors after study completion. [32] A scoping review of 26 
indirect comparisons with IPD showed that 67% of included studies obtained IPD through the 27 
establishment of a collaborative group. [8] Hence, the cooperation of the authors of the primary 28 
studies is crucial for providing IPD in a usable format and answering queries about their data. 29 
Since sharing IPD has legal, ethical, and logistical constraints, we need to understand how to 30 
optimize this process.  31 
Our objective was to examine the impact of providing a small financial incentive to 32 
authors of RCTs that were eligible for a systematic review and NMA, versus usual contact 33 
strategies to obtain IPD. As a secondary objective, we aimed to describe potential barriers and 34 
facilitators associated with the data sharing process. 35 
2. Methods 36 
The study protocol was registered with ClinicalTrials.gov (NCT02569411; October 5th, 37 
2015). Our methods are described briefly here; additional details can be found in the protocol 38 
publication and Additional File 1: Appendix 1, 2. [34] Our RCT conforms to the Consolidated 39 
Standards to Reporting Trials (CONSORT) guidance [35] (Additional File 2). 40 
We used RCTs identified through two systematic reviews and NMAs, [36, 37] and we 41 
followed the process as depicted in Figure 1a. Overall, we contacted both study authors and 42 
study sponsors (Additional File 1: Appendix 2) to obtain IPD.  The process varied across 43 
sponsors (Additional File 1: Appendix 3). 44 
(Figure 1 here) 45 
We performed a descriptive analysis using frequencies and percentages for all 46 
characteristics we either abstracted from trial publications or collected through the author and 47 
sponsor contacting process (Additional File 1: Appendix 2).  48 
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We compared author responses for which we received complete IPD, author response 49 
type (positive vs. negative) and response rate (response vs. no response) between experimental 50 
and control groups using the OR and its corresponding 95% CI. Upon IPD receipt, we assessed 51 
data completion and time needed to share. Since only 2 IPD datasets were available across the 52 
intervention and control groups at the time these analyses were done, we could not compare 53 
the intervention group results according to the IPD characteristics. The OR and its 54 
corresponding 95% CI was used to compare author and sponsor response type and response 55 
rate in the following groups: low vs. high/unclear risk of bias, industry/mixed-sponsored vs. 56 
publicly-sponsored studies, large vs. small-moderate studies, statistically significant vs. non-57 
statistically significant treatment effects, small vs. medium-large effect studies. We assessed for 58 
a trend over publication years to respond using the Cox and Stuart trend test and the trend 59 
library in R. [38] We assessed whether a linear relationship existed between year of publication, 60 
absolute SMD or sample size and days to respond, and calculated a Pearson correlation 61 
coefficient. The distribution of eligible studies by industry sponsor was plotted in a bubble plot 62 
using the ggplot2 library in R. [38] Finally, we outlined barriers and resource requirements that 63 
prevented IPD from being obtained, challenges that delayed the process of obtaining IPD, as 64 
well as monetary costs and personnel resources required to obtain IPD. We also describe the 65 
barriers encountered at the different levels of the author and sponsor contact process. 66 
3. Results 67 
We included 137 studies (29 RCTs for type 1 diabetes mellitus and 108 RCTs for 68 
Alzheimer’s dementia) for which we attempted to obtain IPD by contacting the original authors 69 
and trial industry sponsors (Additional File 1: Appendix 4). The deadline for receiving IPD to be 70 
included in the analyses was February 28th, 2018 (internal deadline set in our team only). In 71 
Additional File 1: Appendix 5 we present the number of eligible studies we requested from 72 
authors and sponsors separately, and the number of studies we were able to acquire IPD. The 73 
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individual study characteristics are reported in Additional File 1: Appendix 6, 7. Additional 74 
information on the results is reported in Additional File 1: Appendix 8. 75 
3.1 Contacting authors for the RCT process 76 
Of the 137 trials, we were unable to locate contact information for 8 authors and these 77 
were subsequently excluded. Of the 8 trials, 3 were allocated to control and 5 were allocated to 78 
intervention. These 8 trials were published between 1998 and 2010, had moderate to large 79 
sample size, low to unclear allocation concealment bias, and low to high incomplete outcome 80 
data bias. Of the 8 trials, 6 were industry sponsored and 2 did not report funding, 3 compared 81 
NPH against glargine, and 5 compared galantamine, rivastigmine, or donepezil against 82 
placebo/no treatment. In total, we included 26 type 1 diabetes studies, of which 20 (77%) 83 
compared NPH, 14(54%) compared glargine, and 16 (62%) compared detemir to an alternative 84 
treatment. Of the 103 Alzheimer’s dementia studies, 57 assessed donepezil (55%), 25 assessed 85 
memantine (24%), 23 assessed galantamine (22%), and 23 assessed rivastigmine (22%) 86 
(Table1). Additional File 1: Appendix 9 presents a CONSORT flow diagram depicting the process 87 
of the RCT and the IPD received across the 2 groups. [35]129 authors were contacted and 82 88 
(64%) responded (of which 37 [45%] responded positively and 45 [55%] responded 89 
negatively); 24 (19%) authors responded after the first invitation email, and the remainder 90 
responded across the 4 other reminders. Of the authors who did not respond (47 [36%]), two 91 
email addresses were deactivated at the second reminder (6 weeks after the initial email), one 92 
email address was deactivated at the third reminder (10 weeks after the initial email), and one 93 
email address was deactivated at the fourth reminder (14 weeks after the initial email) (Figure 94 
2 and Table 2). According to authors of the primary studies, 15 (33%) of the negative responses 95 
were due to lack of resources or time, lack of ownership or IPD, and old IPD that could not be 96 
retrieved. Of the positive responses, none of the authors shared their IPD. 97 
(Tables 1 and 2 here) 98 
(Figure 2 here) 99 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
9 
The response type (OR=1.13 95% CI [0.47, 2.69]) and the response rate (OR=1.25 95% 100 
CI [0.61, 2.57]) were balanced in intervention and control groups (Additional File 1: Appendix 101 
6). The response rates when the type 1 diabetes studies were categorized per treatment, ranged 102 
between 70% (in NPH) and 85% (in glargine); in which the positive response rates ranged from 103 
29% (in NPH) to 50% (in detemir). The response rates for the Alzheimer’s dementia treatments 104 
ranged between 52% (in rivastigmine) and 65% (in galantamine), with positive responses 105 
ranging from 40% (in galantamine) to 50% (in donepezil) (Table 2).  The response type and 106 
response rate categorized per study characteristics are presented in Appendix 10. 107 
The number of days required for an author to respond ranged from 0 to 117 days (mean 108 
days=45, standard deviation [SD]=39), irrespective of the response type (mean days for positive 109 
response=40, SD=38; mean days for negative response=49, SD=40). Similarly, the number of 110 
days required for an author in the intervention group to respond ranged from 0 to 117 days 111 
(mean days=40, SD=40), irrespective of the response type (mean days for positive response=32, 112 
SD=35; mean days for negative response=48, SD=43), and the number of days required for an 113 
author in the control group to respond ranged from 0 to 116 days (mean days=49, SD=38; mean 114 
days for positive response=50, SD=40, range [1,113]; mean days for negative response=49, 115 
SD=37, range [0, 116]).   116 
3.2 Contacting sponsors and IPD databases 117 
Of the 137 studies, 107 reported at least one industry-sponsored funder in their 118 
publication. In the remaining studies, 11 were publicly-sponsored and 19 did not report any 119 
information about funding. The 19 studies that did not report funding information were 120 
published in journals requiring disclosures for: COI (1 [5%] study), COI/funding (2 [11%] 121 
studies), funding (2 [11%] studies), sponsor (9 [47%] studies), and not available (5 [26%] 122 
studies (Additional File 1: Appendix 6, 7). Across the 107 studies that reported sponsor 123 
information, 17 different industry sponsors were reported in the publications and 24 (23%) 124 
studies reported at least two different sponsors (Additional File 1: Appendix 11). In total, we 125 
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contacted 17 industry sponsors (4 of which collaborate with 2 IPD databases) for 133 studies 126 
(or 107 unique studies, since some studies reported multiple sponsors, where 83 studies were 127 
funded by 1 sponsor, 23 studies by 2 sponsors, and 1 study by 5 sponsors; see Additional File 1: 128 
Appendix 12for list of co-sponsored studies); 3 sponsors (18%) did not respond to any of our 129 
contact attempts. We contacted industry sponsors only, as we were not able to locate the 130 
contact information for the majority of the included public sponsors. In the following, we refer 131 
to the term ‘sponsor’ to indicate an industry sponsor. CSDR and YODA databases facilitated data 132 
sharing for 59 trials funded by 4 sponsors who made 18 trials available. In total, we included 25 133 
type 1 diabetes studies, of which 20 (80%) compared NPH, 15 (60%) compared detemir, and 13 134 
(52%) compared glargine to an alternative treatment. Of the 108 Alzheimer’s dementia studies, 135 
69 assessed donepezil (64%), 26 assessed galantamine (24%), 23 assessed rivastigmine (21%), 136 
and 20 assessed memantine (19%) (Additional File 1: Appendix 13). Additional File 1: Appendix 137 
14 shows the number of eligible studies per sponsor and per type of response regarding IPD 138 
availability. The response rate when the type 1 diabetes studies were categorized per treatment 139 
was 100% across all treatments. The positive response rates ranged from 15% (in glargine) to 140 
80% (in detemir). The response rates for the Alzheimer’s dementia treatments ranged between 141 
85% (in memantine) and 100% (in galantamine), with positive responses ranging from 19% (in 142 
galantamine) to 29% (in memantine). Of the total 133 studies, 38 (29%) unique studies were 143 
deemed available by the sponsors. However, the majority (89 studies; 67%) of the IPD were 144 
unavailable and the reasons for refusal of providing IPD varied, including difficulty with study-145 
identification (46%), non-ownership of IPD (26%), and the age of the study (too old, 12%) 146 
(Table 3, Additional File 1: Appendix 15).  147 
Up until February 28th, 2018 and within 318 days of contacting the sponsor, we received 148 
2 complete IPD datasets from a single sponsor of 136 and 123 patients. We determined the 149 
dataset complete according to the study protocol. Allocation concealment was rated as low risk 150 
of bias for both studies; however, for incomplete outcome data, one study had low risk of bias 151 
and one had a high risk of bias. Up until February 28th, 2018 we also had another data sharing 152 
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agreement signed by both parties for 12 unique studies. The time to clarify the data sharing 153 
agreement process ranged between 0 and 24 days, whereas the time to approve the data 154 
sharing agreement ranged between 86 and 168 days. All sponsors who agreed to share their IPD 155 
with us restricted its availability through a password protected, software-restricted, and closed 156 
environment within a certain period of time ranging between 28 and 730 days.  The exploration 157 
of response rate and response type across different study characteristics suggested effect sizes 158 
with wide CIs for most point estimates (Additional File 1: Appendix 16,17).  159 
(Table 3 here) 160 
3.3 Barriers and resource requirements associated with the IPD 161 
acquisition 162 
Several barriers and challenges were encountered during the IPD acquisition process. In 163 
Table 4 we provide the barriers we encountered during the author and sponsor contact process 164 
separately. The barriers and challenges are also depicted with different icons at the various 165 
levels of the author contact process in Figure 1b, and of the sponsor contact process in Figure 166 
1c.  167 
(Table 4 here) 168 
An important barrier in obtaining study IPD was the identification of the underlying trial 169 
data set, such as when an old study could not be easily located or when its data were lost by an 170 
author. Also, studies may not have been identifiable by sponsors when certain information was 171 
not available, such as the NCT number, due to the relatively recent widespread use of trial 172 
numbers (since 2005). In some cases, even when conducting exhaustive searches (Additional 173 
File 1: Appendix 18), an NCT number (or other related study ID) was difficult to find or did not 174 
exist, and hence sponsors could not locate the study in their database solely based on the study 175 
citation details. Being unable to match study publication to the underlying studies when 176 
sponsors needed to be contacted was the most frequent reason for IPD being unavailable (see 177 
Figure 8). Of the 98 studies with unavailable IPD, 41 (42%) studies could not be located by the 178 
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study sponsor. Another important barrier was data ownership. It was often the case that study 179 
authors did not own the IPD, the study funder had to be contacted to request the IPD (56 180 
[43%]). This also applied to sponsors. For instance, since 18 of the eligible studies were co-181 
sponsored by Eisai and Pfizer (see Additional File 1: Appendix 11), both sponsors were 182 
contacted to confirm ownership. Data ownership was the second most frequent reason (25 183 
studies [26%]) for unavailable IPD (see Additional File 1: Appendix 15). A barrier associated 184 
with the analysis once IPD was received was that IPD were only available through proprietary 185 
sponsor-specific platforms. This does not allow for IPD from different sponsor platforms to be 186 
combined (and could be a challenge for those who are unfamiliar with the software provided in 187 
the underlying platform). As the IPD could not be combined from all studies identified in a 188 
systematic review in a single place and model, a one-stage analysis was impossible. Also, the 189 
time that the platform permitted access to the IPD was often limited (e.g., 6 weeks) which is a 190 
significant constraint given that IPD from different studies could be available at different time 191 
points. However, this required knowledge of the data items and times for access available from 192 
each sponsor. 193 
4. Discussion 194 
Our results showed that offering small financial incentives to study authors does not 195 
improve IPD retrieval. In our particular example, by the end of July 2017 we were unable to 196 
obtain any IPD datasets from trial authors, and were only able to obtain two IPD datasets after 197 
contacting industry sponsors. We found that obtaining a response from authors to requests to 198 
access IPD may depend on study characteristics. Authors of publicly-sponsored studies, those 199 
that included between <50 and 150 patients, and those with a medium to large treatment effect 200 
(i.e., an estimated treatment above 0.2 on the SMD scale) tended to respond positively to IPD 201 
requests. Increased odds of a positive response were also found in studies at high risk of bias. 202 
This is because small to moderate studies are typically at high risk of bias in most domains and 203 
are associated with large treatment effects. In contrast, IPD availability from sponsors tended to 204 
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be positive for large (>150 patients), and low risk of bias studies, with small and non-205 
statistically significant treatment effects. This suggests that well-conducted industry sponsored 206 
studies are more likely to be shared. It should be highlighted that there is a high risk of 207 
confounding in our results, as large studies are typically associated with small treatment effects 208 
and low risk of bias. In addition, these findings should be interpreted with caution, as our 209 
estimated ORs were associated with wide confidence intervals. This high uncertainty in ORs 210 
may be associated with low power to detect the true effect. Similarly, the marginally non-211 
statistically significant trend of positive author/sponsor responses across publication years 212 
favouring newer RCTs may be associated with the low power of the test.  213 
Sharing IPD may be constrained by a number of legal, ethical, and logistical factors, 214 
which may deter researchers from undertaking them and trial investigators participating in 215 
them. This may perpetuate reliance on the conduct of aggregate data meta-analysis and NMA 216 
that may reduce statistical power and accuracy of results. Significant barriers in obtaining study 217 
IPD from trial sponsors may include matching study publication to the underlying study,, issues 218 
around data ownership, and acquiring of data dictionary licenses.  219 
In general, time and cost may be a barrier to carrying out an IPD NMA.  Costs include not 220 
only staff wages, including administrative, legal, library, and research staff, but also license costs 221 
(when applicable, e.g. WHO Drug Dictionary license approximate cost $8,958.25 USD per 222 
sponsor). We were surprised to encounter the licence cost issue as it has not been encountered 223 
previously in the context of collaborative group IPD meta-analyses and could be an isolated 224 
experience or an additional cost of obtaining data from trial sponsors and data repositories.  225 
The longer time required to conduct this type of research may be considered an additional 226 
barrier, especially when time-sensitive decisions need to be made. Our findings show that 227 
obtaining study IPD can take longer than a year after a sponsor’s positive response. Thus, 228 
accessing data via repositories may not be as rapid as was hoped and therefore, we recommend 229 
that in accordance with customary practice in collaborative IPD meta-analyses, future planning 230 
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of IPD meta-analyses that involve obtaining data from trial sponsors through data sharing 231 
platforms should include sufficient time for the IPD retrieval process, (probably at least two-232 
years). For example, the IPD retrieval process for a recently published IPD-NMA of 10 233 
antiepileptic drugs required 4 years to obtain the 65% of the included participants and 38% of 234 
identified clinical trials. [39] Even if access to IPD is granted,, additional barriers may arise, such 235 
as having to analyze IPD datasets using different sponsor data sharing platforms and software 236 
making one-stage analysis impossible. Being able to access IPD only for a limited time (e.g. 4 to 237 
6 weeks) is also a serious limitation and constraint as when analysing IPD from different studies 238 
provided by different sponsors, the IPD datasets can be available at different time points.  and 239 
different data variables may be available.  240 
A limitation of our RCT is that we did not anticipate that the trial authors would not have 241 
authority to grant access to the data sets and that sponsors would need to be contacted instead. 242 
We contacted each author about a single study to avoid contamination bias in our RCT.  Through 243 
this process, we avoided sending multiple requests to a single author. If an author directed us to 244 
another co-author then we discussed all papers with them. However, in a usual IPD project 245 
aiming to collect IPD from a number of studies, if multiple studies from the same research group 246 
are of interest, one would probably request IPD from all these studies at once to maximise the 247 
amount of data provided. Also, the time available to conduct the analysis in this study was 248 
probably another barrier in obtaining IPD.  Another limitation is that blinding to treatment 249 
allocation was only possible for the statistician who conducted the analysis. Due to the nature of 250 
the intervention and the study design, blinding was impossible for research personnel and 251 
outcome assessors. However, given that neither group has contributed data, the unsuccessful 252 
blinding has not impacted our success rate. To reduce potential bias in the author responses 253 
received, we planned to send authors a debriefing letter at the end of the trial informing them 254 
that they participated in a RCT. Also, to avoid misinterpretation of the small financial sum 255 
offered as compensations for the effort involved in the preparation of IPD, we proposed our 256 
IPD-NMA as a collaborative project. If the authors met the ICMJE criteria [40] and shared their 257 
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IPD, they would be included in the collaborative group authorship of the final publication.  The 258 
authors’ reluctance to share their IPD could be due to the contact person’s expertise outside the 259 
clinical field relevant to the trial.  However, to increase author responses, an experienced 260 
Scientist (ACT) in the field of systematic reviews and meta-analyses contacted each author and 261 
provided citations of our published protocols, where researchers with significant reputations in 262 
the relevant fields were included as co-authors. Also, in our communication with the trialists we 263 
indicated our experience in the fields through our published systematic reviews in the area, 264 
which were funded through the Canadian Institutes of Health Research. An additional limitation 265 
is that we used different outcomes across studies to explore the association between response 266 
rate (and type) and the magnitude of treatment effect. In total, we used 62 studies with MMSE, 267 
26 studies with serious adverse events, and 25 studies with A1c reported as the outcome 268 
measure. Although it is expected that the treatment effect will vary across outcomes, this was 269 
the only feasible approach to include the most data possible to explore this association. Another 270 
limitation is that we used studies examining response rates from surveys to inform our study 271 
size, [41-44] since to the best of our knowledge no studies assessing response rate in retrieving 272 
IPD from RCTs using a financial incentive is available. This may have underestimated the 273 
required sample size, producing imprecise results. Our findings represent retrieving IPD from 274 
authors for two certain clinical areas (type 1 diabetes and Alzheimer’s dementia), and these 275 
might not be well generalized to other drug trials. It should be noted though that the majority 276 
(77%) of the included RCTs were sponsored by pharmaceutical companies, and this may have 277 
affected the IPD retrieval. 278 
Before deciding to conduct an IPD meta-analysis or NMA, one should consider and 279 
weigh up the benefits and limitations of the approach. Although the process of sharing IPD may 280 
vary according to the disease, treatment, and clinical question addressed, [45] one should not 281 
only consider the cost and time needed to conduct an IPD meta-analysis or NMA, but also the 282 
possibility of being unsuccessful in retrieving IPD. [33] This may be particularly important for 283 
NMAs that involved large numbers of studies. When IPD meta-analyses fail to obtain data the 284 
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impact of this on the analyses should be considered, especially when IPD are missing not at 285 
random (e.g. when acquirement of IPD depends on the RCT characteristics). This could threaten 286 
validity and in turn impact clinical decision-making as the practice of evidence-based medicine 287 
relies on the availability of timely, relevant, and scientifically sound data on the risks and 288 
benefits associated with medical interventions. Important initiatives to reporting study results 289 
are currently being made by medical journals via encouraging authors to use the CONSORT 290 
checklist, [35] as well as by study authors and organizations (see http://www.alltrials.net/). 291 
[19-22] However, as our results showed, IPD sharing is not yet well-established in the fields of 292 
type I diabetes and Alzheimer’s dementia, and more efforts are required to achieve this goal. 293 
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Tables 342 
Table 1: Author response per treatment  343 
Type 1 Diabetes (N=26 studies) Alzheimer’s Dementia (N=103 studies) 
 
Detemir Glargine NPH Donepezil Galantamine Memantine Rivastigmine 
Positive response 6 4 4 17 6 7 6 
Negative response 6 8 10 17 9 7 6 
Response* 12 12 14 34 15 14 12 
No response 4 2 6 23 8 11 11 
Total studies 16 (62%) 14 (54%) 20 (77%) 57 (55%) 23 (22%) 25 (24%) 23 (22%) 
Footnotes: * Combined total of positive and negative responses 344 
Abbreviations: NPH, neutral protamine Hagedorn345 
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Table 2: Author Response Summary 346 
# of authors contacted 129 
# of authors who did not respond 47 (36%)* 
# of authors who responded: 82 (64%) 
# of authors who responded after first email 24 (0 to 15 days) 
# of authors who responded after second email 21 (20 to 48 days) 
# of authors who responded after third email 18 (50 to 83 days) 
# of authors who responded via post mail 0 
# of authors who responded after fourth email 14 (86 to 100 days) 
# of authors who responded after fifth email 5 (105 to 117 days) 
# of authors who responded via phone 5† 
Negative response: 45 
Contact funder/database 27 (60%) 
Lack of resources/time  5 (11%) 
Do not have approval/ownership 4 (9%) 
Do not have data 3 (7%)‡ 
Old data 3 (7%) 
Not interested 2 (4%) 
Contact corresponding author 1 (2%) 
Positive response: 37 
Contact corresponding author/funder - provided contact person 20 (54%) 
Contacted funder 5 (14%) 
Interested but did not follow-up 12 (32%) 
Time to respond (days) 0 to 117  
Time to obtain data sharing approval (days) 467 
Footnotes:  347 
* Two email addresses were deactivated at the second reminder (6 weeks after the initial email), one 348 
email address was deactivated at the third reminder (10 weeks after the initial email), and one email 349 
address was deactivated at the fourth reminder (14 weeks after the initial email). 350 
†5 calls were answered [Message left with admin (1); Language barrier (4)] 351 
‡2 authors mentioned that they did not have the data available. 1 author mentioned that the data was 352 
destroyed353 
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Table 3: Sponsor Response Summary 354 
Number of sponsors/databases* contacted: 17 
Number of sponsors who did not respond: 3 (6 studies) † 
Number of sponsors where data was unavailable: 
13 (89 studies) 
‡  
Cannot identify study 4 (41 studies) 
Cannot share data  6 (22 studies) 
Language  1 (1 study) 
Old study  2 (11 studies)  
Phase 4 study  1 (4 studies)  
Potential business considerations under review 1 (1 study)  
No details provided 1 (5 studies)  
Do not own data 10 (23 studies) 
IPD not available  1 (3 studies)  
Number of sponsors who required a research proposal to be submitted first: 
7 (91 studies) 
§ 
Research proposal approved 5 (64 studies) 
Research proposal not approved (no reason provided) 1 (5 studies) 
Research proposal under review 1 (22 studies) 
Number of sponsors who required a research proposal and data sharing agreement 
(DSA) to be submitted congruently:  4 (24 studies)¶ 
Research proposal approved and DSA approved 1 (15 studies) 
Research proposal approved and DSA not approved (do not own data) 1 (2 studies) 
Research proposal and DSA under review 2 (7 studies) 
Number of studies where study identification number was required  62 
Number of studies where author was contacted for study identification number 48 
Number of studies where author provided study identification number 7 
Number of studies where author did not provide study identification number: 41 
No response 30 
Does not have the information 4 
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Referred to sponsor 3 
Does not have access to the information 2 
Referred to lead PI of the study 1 
Not registered 1 
Number of studies where study identification number was found  13 
Time to clarify data sharing process (days) 0 to 24 days 
Time to approve research proposal (days) 22 to 121 
Time to approve data sharing agreement (days) 86 to 168 
Number of studies requested  137 
Number of studies available 38 
Number of studies shared 11 
Footnotes: 355 
* ClinicalStudyDataRequest.com (CSDR); Yoda.Yale.edu (YODA) 356 
† Merz, ONO, Roivant 357 
‡ Abbvie, Daiichi-Sankyo, Eisai, Forest Laboratories/Allergen, GlaxoSmithKline, Janssen, Lundbeck, 358 
Novartis, Novo Nordisk, Pfizer, Shire Pharmaceuticals, Takeda 359 
§ Abbvie, CSDR, Forest Laboratories/Allergen, Janssen, Pfizer 360 
¶ AstraZeneca, Lundbeck, Novo Nordisk, Shire Pharmaceuticals361 
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Table 4: Barriers and Resource requirements 362 
Activity/Item 
Contacting Authors Contacting Sponsors Resources 
Issue Impact Issue Impact 
Initial Contact 
Cannot locate contact 
information (email 
address, mailing 
address and/or 
phone number)  
Spent extra 
time finding 
current contact 
information for 
authors 
Unable to 
invite authors 
to participate 
 
Unable to locate an ‘obvious’ 
contact for IPD requests 
Sponsors did not respond to 
initial contact 
Spent extra time 
pursuing multiple 
avenues and 
contacting multiple 
sponsors (for co-
sponsored studies) 
before finding the 
correct one 
Research staff 
1 research assistant 
3 research coordinators 
2 scientists 
Administrative staff 
2 administrative assistants 
Ongoing 
Communication 
Emails become 
undeliverable 
Postal mail returned 
Initial contact directs 
to a co-author that is 
already part of the 
RCT 
Authors do not 
respond (either to 
initial contact or later 
communication) 
Loss to follow-
up: unable to 
pursue any 
further 
No direct avenues for 
communication with sponsors 
(e.g. general inquiry only) 
Multiple departments/teams 
involved in communication 
Difficult to follow-up 
with sponsors when 
no response is 
received 
Extra time needed to 
relay updates to 
sponsors 
Research staff 
1 research assistant 
1 research coordinator 
Administrative staff 
2 administrative assistants 
Legal staff 
1 research contract specialist 
1 research contract analyst 
Incentives/communication 
Gift cards (incentives for 
intervention) 
Post mail (reminder) 
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Long distance phone charges 
(reminder) 
Application Process 
Not applicable Not applicable Differing 
requirements/processes 
between sponsors 
Additional items required by 
sponsors (e.g., additional 
training/agreements) 
Sponsors changed methods for 
application when application 
was in process 
Significant delays to 
obtaining IPD  
Research Staff 
1 research assistant 
1 research coordinator 
2 scientists 
Administrative staff 
2 administrative assistants 
Legal staff 
1 research contract specialist 
1 research contract analyst 
Identifying Studies 
Study is ‘too old’ to 
find/share data 
Unable to 
obtain IPD 
from author 
Could not identify studies with 
available information 
Additional 
time/resources used 
to find trial 
identifiers/study 
information 
Research Staff 
1 research assistant 
1 research coordinator  
Library staff 
1 information specialist 
Legal Agreements 
Not applicable Not applicable Multiple revisions 
Regulations differ between 
countries 
Document formats (un-editable, 
need physical copies) 
Time-consuming, 
lengthens agreement 
process 
Difficult to revise/edit 
documents 
Research Staff 
1 research assistant 
1 research coordinator 
2 scientists 
Administrative staff 
2 administrative assistants 
Legal staff 
1 research contract specialist 
1 research contract analyst  
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Data Ownership 
Study authors do not 
‘own’ data 
Authors unable 
to share IPD 
Sponsors do not own data  We cannot identify 
who owns the data 
and thus cannot 
obtain IPD 
Extra time and 
resources needed to 
identify ‘true’ data 
owners 
Research Staff 
1 research assistant 
1 research coordinator  
Data Sharing/Receiving 
Data 
Lack of available 
resources 
Ethics restrictions on 
data sharing 
Authors unable 
to share IPD 
‘Out of scope’ of data sharing 
policy 
Unable to share all data from 
different studies at once 
Data only available through 
sponsor platforms 
Additional licenses required to 
access the data 
Data only available for a 
specified amount of time 
Unable to obtain IPD 
Access to data is 
limited 
Unable to conduct 
one-stage analysis 
Additional cost or 
unable to obtain IPD 
Research Staff 
1 research assistant 
1 research coordinator 
1 scientist 
2 research managers 
Licensing 
WHO Drug Dictionary 
Approximately $8,958.25 USD 
/sponsor 
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Figures 363 
Figure 1. Process of study for acquisition of IPD (a) through an author (b), and a sponsor (c), 364 
along with the barriers encountered at each step 365 
Figure 2. Author response frequency by type of response and group author allocated per contact 366 
reminder 367 
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What is New? 
 
Key Findings 
• Significant barriers were encountered in obtaining study individual participant data (IPD). 
These included identifying trial data based on published reports and other sources, 
negotiating data ownership (for both authors and sponsors), and limited data access 
(including time, ability to share data, and special software needed) 
What this adds to what is known? 
• Likelihood of sharing IPD may be associated with study-specific characteristics, such as 
funding type, study size, study risk of bias, and treatment effect. For example, authors of 
publicly-sponsored studies with medium-large treatment effect (i.e., an estimated 
treatment effect above 0.2 on the standardized mean difference scale) tended to respond 
positively to IPD requests. Availability of IPD from sponsors tended to be positive for large 
studies with a low risk of bias 
• The time taken to obtain IPD was longer than a year after a sponsor’s positive response. 
Data sharing agreements were required for all sponsors. Clarifications from sponsors 
regarding the agreements ranged between 0 and 24 days. Approval of data sharing 
agreements ranged between 86 and 168 days 
What is the implication and what should change now? 
• Sharing IPD has legal, ethical, and logistical constraints, which may deter researchers from 
embarking on these projects and may deter trial participants from participating. This may 
reinforce reliance on aggregate data (network) meta-analysis that may have inadequate 
statistical power and accuracy, reducing the quality of evidence available to health 
professionals, policymakers, and patients.  
• Our findings show that obtaining study IPD can take longer than a year after a sponsor’s 
positive response. Therefore, we recommend that future planning of IPD meta-analyses 
should provide sufficient time (e.g. at least a year) for the IPD retrieval process, 
particularly in clinical areas where the approach is not yet established. 
 
